MRVIMaravai LifeSciences Holdings Inc - Ordinary Shares - Class A
$5.22
$0.21
(4.19%)
Closed $5.22
$0.00
(0.00%)
After Hours
EarningsAug 10
Mkt Cap$1.29B
Vol1.92M
Fundamentals
TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
TriLink, part of Maravai LifeSciences (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA...
Business Wire
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio...
Yahoo! Finance: News
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility...
Business Wire
Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief...
Business Wire
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
Maravai LifeSciences (MRVI) delivered earnings and revenue surprises of +121.41% and +20.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Maravai LifeSciences Reports First Quarter 2026 Financial Results
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the...
Business Wire
All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy
Maravai LifeSciences (MRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Brokerages
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are currently covering the stock, Marketbeat reports...
MarketBeat
Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates
Baxter (BAX) delivered earnings and revenue surprises of +15.42% and +3.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Maravai LifeSciences (MRVI) Expected to Announce Earnings on Thursday
Maravai LifeSciences (NASDAQ:MRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest MRVI News
ViewTriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale
Business Wire
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio
Yahoo! Finance: News
Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
Business Wire
Advertisement|Remove ads.